Qiagen N.V.

NYSE:QGEN

Medical - Diagnostics & Research

Healthcare
$49.56 -0.96%

-$0.35 today

Market cap
$10.23B
Beta
0.66
P/E (TTM)
18.6
EPS (TTM)
$1.94
Dividend yield
0.69%
52W Low $32.53High $57.82

Volume 4.26M

Average 2.07M

QGEN Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Qiagen N.V.NYSE: QGEN

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development grows in line with its trailing trend

Q2 FY2026 research & development of $50.43M rose 5.6% year over year, in line with the +5.5% change in trailing-twelve-month research & development. Sequentially, it rose 4.5% from the prior quarter. Over 3 fiscal years it compounded at -0.4% a year.

Context

  • Research & development amounted to 9.0% of revenue in FY2025, down 0.8 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +5.6% holds above the trailing-twelve-month pace of +5.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$50.43M+4.5% QoQ
Last fiscal yearDec 2025
$187.52M-3.1% YoY
LTMJun 2026
$194.67M+5.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.6%——
1 year-3.1%——
3-year CAGR-0.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
187.52M USD
Year-over-year change
-3.1%
4-year CAGR
-0.3%

Research & Development vs competitors

How QGEN compares with its peers on the latest reported figures

  • QGEN's LTM Jun 2026 research & development of $194.67M is the 8th highest of the 11 companies compared; the peer median is $241.82M.
  • Its year-over-year change of +5.5% is the 4th highest of 11, against a peer median of +1.8%.
  • Research & development amounts to 9.3% of revenue for QGEN, versus a peer median of 7.6%.
QGEN Competitors Peer median
Research & Development for QGEN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DHRDanaher CorporationLTM Sep 2026$1.67B +4.2%+1.5%6.5%
TMOThermo Fisher Scientific Inc.LTM Sep 2026$1.41B -0.7%-1.7%3.0%
AAgilent Technologies, Inc.LTM Jul 2026$485M +8.5%-0.9%6.6%
BRKRBruker CorporationLTM Jun 2026$393.5M -1.6%+18.8%11.2%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$261.1M -14.3%+0.0%10.1%
TXG10x Genomics, Inc.LTM Sep 2026$222.54M -10.9%-3.5%36.0%
RVTYRevvity, Inc.LTM Jul 2026$215.83M +5.2%-0.9%7.4%
QGENQiagen N.V.LTM Jun 2026$194.67M +5.5%-0.4%9.3%
TECHBio-Techne CorporationLTM Sep 2026$96.87M -3.0%+0.8%7.9%
RGENRepligen CorporationLTM Jun 2026$55.23M +14.4%+7.2%7.0%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$21.15M +13.2%+8.3%10.1%
Peer median (excluding QGEN) $241.82M+1.8%+0.4%7.6%

Competitors are the stored peer set for QGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.25B2.14B1.97B1.98B2.09B
Cost of Revenue800.84M756.96M731.62M1.01B798.5M
Gross Profit1.45B1.38B1.23B967.35M1.29B
Gross Margin64.4%64.7%62.8%48.9%61.8%
Research & Development189.96M189.86M198.51M193.49M187.52M
Selling, General & Admin584.47M603.95M579.17M564.36M583.67M
Operating Expenses820.74M853.1M823.75M869.64M771.19M
Depreciation & Amortization214.93M208.4M205.34M203.27M193.75M
EBITDA895.24M779.36M688.56M368.26M717.27M
EBITDA Margin39.8%36.4%35.0%18.6%34.3%
Operating Income630.08M531.46M409.94M97.71M520.31M
Operating Margin28.0%24.8%20.9%4.9%24.9%
Interest Income9.56M32.76M78.99M68.02M64.32M
Interest Expense54.48M58.36M53.41M43.84M33.26M
Other Income / Expenses(4.25M)(18.86M)19.87M23.44M(30.04M)
Income Before Tax625.83M512.6M429.81M121.15M490.27M
Pre-Tax Margin27.8%23.9%21.9%6.1%23.5%
Income Tax Expense113.23M89.39M88.51M37.56M65.39M
Net Income512.6M423.21M341.3M83.59M424.88M
Net Margin22.8%19.8%17.4%4.2%20.3%
EPS (Basic)2.522.081.670.392.04
EPS (Diluted)2.472.051.650.382.04
Weighted Avg Shares221.14M220.75M217.49M216.44M207.94M
Weighted Avg Shares (Diluted)225.07M223.23M217.49M218.48M207.94M

Qiagen N.V.

NYSE:QGEN

Intrinsic Alpha fair value

Locked

Current Price

$49.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.